Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL NASDAQ:GOVX NASDAQ:VUZI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.04-4.6%$1.12$0.77▼$2.24$89.38M1.02446,181 shs601,125 shsGOVXGeoVax Labs$0.56-7.4%$0.68$0.43▼$3.88$8.85M3.31979,024 shs1.26 million shsVUZIVuzix$3.52-8.3%$2.53$0.85▼$5.79$272.24M1.691.97 million shs2.96 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics+0.93%+3.81%+5.83%-15.50%-40.44%GOVXGeoVax Labs+2.93%+8.11%-12.92%-11.20%-73.09%VUZIVuzix-5.42%+1.32%+66.96%+59.34%+190.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.04-4.6%$1.12$0.77▼$2.24$89.38M1.02446,181 shs601,125 shsGOVXGeoVax Labs$0.56-7.4%$0.68$0.43▼$3.88$8.85M3.31979,024 shs1.26 million shsVUZIVuzix$3.52-8.3%$2.53$0.85▼$5.79$272.24M1.691.97 million shs2.96 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics+0.93%+3.81%+5.83%-15.50%-40.44%GOVXGeoVax Labs+2.93%+8.11%-12.92%-11.20%-73.09%VUZIVuzix-5.42%+1.32%+66.96%+59.34%+190.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.00Buy$8.00669.23% UpsideGOVXGeoVax Labs 2.50Moderate Buy$8.501,430.43% UpsideVUZIVuzix 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest VUZI, GOVX, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CRDLCardiol TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GOVXGeoVax LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025VUZIVuzixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/1/2025VUZIVuzixCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/27/2025CRDLCardiol TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GOVXGeoVax LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025VUZIVuzixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/26/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.009/17/2025CRDLCardiol TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/7/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.007/29/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AGOVXGeoVax Labs$6.14M1.44N/AN/A$0.48 per share1.16VUZIVuzix$5.53M49.19N/AN/A$0.51 per share6.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-232.26%-158.19%11/13/2025 (Estimated)GOVXGeoVax Labs-$24.99M-$2.01N/AN/AN/A-403.88%-408.80%-279.89%11/11/2025 (Estimated)VUZIVuzix-$73.54M-$0.51N/A∞N/A-707.90%-113.11%-101.83%11/13/2025 (Estimated)Latest VUZI, GOVX, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CRDLCardiol Therapeutics-$0.11-$0.07+$0.04-$0.07N/AN/A8/14/2025Q2 2025VUZIVuzix-$0.12-$0.10+$0.02-$0.10$1.63 million$1.30 million7/28/2025Q2 2025GOVXGeoVax Labs-$0.41-$0.35+$0.06-$0.35$0.37 million$0.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/AVUZIVuzixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.012.462.46GOVXGeoVax LabsN/A2.032.03VUZIVuzixN/A7.686.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%GOVXGeoVax Labs6.09%VUZIVuzix35.87%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%GOVXGeoVax Labs1.20%VUZIVuzix8.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2085.94 million81.43 millionNot OptionableGOVXGeoVax Labs1015.93 million15.73 millionNot OptionableVUZIVuzix11077.34 million70.92 millionOptionableVUZI, GOVX, and CRDL HeadlinesRecent News About These CompaniesVuzix's (VUZI) "Sell (E+)" Rating Reaffirmed at Weiss RatingsOctober 9 at 7:58 PM | marketbeat.comVuzix files to sell 4.2M shares of common stock for holdersOctober 8 at 8:26 PM | msn.comCraig-Hallum Reaffirms Their Buy Rating on Vuzix (VUZI)October 4, 2025 | theglobeandmail.comWhat Recent Defense Deals and Partnerships Mean for Vuzix’s Growth StoryOctober 4, 2025 | finance.yahoo.comVuzix, Bundlar partner to deliver no-code XR content across Vuzix Smart GlassesOctober 2, 2025 | msn.comWhy Is Vuzix Corporation Stock Soaring Thursday?October 2, 2025 | benzinga.comVuzix and BUNDLAR Partner to Deliver No-Code XR Content Across Vuzix Smart Glasses to the Enterprise and Defense MarketsOctober 2, 2025 | prnewswire.comVuzix price target raised to $6 from $3 at Craig-HallumOctober 1, 2025 | msn.comVuzix Expands OEM Defense Program Base with New Six-Figure Waveguide Development Order from a Leading U.S. Defense ContractorSeptember 29, 2025 | prnewswire.comSmart glasses quietly transmitting facial recognition scansSeptember 25, 2025 | msn.comVuzix Target of Unusually High Options Trading (NASDAQ:VUZI)September 24, 2025 | marketbeat.comVuzix and TCL CSOT Expand Partnership to Deliver a Total Optical Solution Featuring Advanced, Compact, High-Brightness MicroLED and Production-Ready Waveguide OpticsSeptember 23, 2025 | prnewswire.comVuzix Completes Final Tranche with Quanta ComputerSeptember 23, 2025 | tipranks.comGoldman Sachs Group Inc. Buys 162,229 Shares of Vuzix Corporation $VUZISeptember 23, 2025 | marketbeat.comVuzix achieves milestones tied to investment agreement with QuantaSeptember 22, 2025 | msn.comVuzix Achieves Waveguide Production Milestones and Receives Additional $5 Million Quanta Investment, Bringing Total Funding to $20 MillionSeptember 22, 2025 | prnewswire.comSaphlux and Vuzix Collaborate to Advance AR Display and Glasses SolutionsSeptember 19, 2025 | prnewswire.comGesture-Control Wearables Redefine Human-Technology InteractionSeptember 17, 2025 | newswire.caVuzix (NASDAQ:VUZI) Share Price Passes Above Fifty Day Moving Average - Should You Sell?September 17, 2025 | marketbeat.comVuzix to Highlight Key OEM & Waveguide Manufacturing Capabilities at Vision Expo West 2025September 15, 2025 | prnewswire.comVuzix Corporation Appoints RealWear Co-Founder Dr. Chris Parkinson as President, Enterprise SolutionsSeptember 11, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVUZI, GOVX, and CRDL Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.04 -0.05 (-4.59%) Closing price 04:00 PM EasternExtended Trading$1.06 +0.02 (+2.40%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.GeoVax Labs NASDAQ:GOVX$0.56 -0.04 (-7.43%) As of 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Vuzix NASDAQ:VUZI$3.52 -0.32 (-8.33%) Closing price 04:00 PM EasternExtended Trading$3.49 -0.03 (-0.85%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vuzix Corporation designs, manufactures, and markets smart glasses and augmented reality (AR) technologies and products for the enterprise, medical, defense, and consumer markets. The company's products include head-mounted smart personal display and wearable computing devices that offer users a portable viewing experience, provide solutions for mobility, wearable displays, and augmented reality, as well as original equipment manufacturer waveguide optical components and display engines. It also provides certified ERP SaaS logistics solution to support hand-held mobile phones and scanners used in logistics, warehousing, and manufacturing applications. It holds approximately 375 patents and patents pending and various IP licenses in the fields of optics, head-mounted displays, and augmented reality Video Eyewear field. It sells its products through resellers, distributors, direct to commercial customers, and online stores, as well as various Vuzix operated web stores in North America, Europe, the Asia-Pacific, and internationally. The company was formerly known as Icuiti Corporation and changed its name to Vuzix Corporation in September 2007. Vuzix Corporation was incorporated in 1997 and is headquartered in West Henrietta, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
